Artificial intelligence will be highlighted on Intrasense™ booth (#6956). The new version of Myrian® platform enabling artificial intelligence to truly be embedded into the daily workflow and clinical routine.
All innovations will be presented at JFR 2019 on the Intrasense ™ booth (# 213A). The new version of Myrian® as well as the XP-Mammo application will be display.
This new version of Myrian® brings many clinical innovations and a new application.
Achieving a positive Net Income within this first 2019 semester validates the strategic choices set by the new governance in 2018, generating profits for the first half of 2019 financial year.
Myrian® XP-Mammo, can now be commercialized on the European market.
Myrian® XP Prostate, the new reference tool for worldwide prostate experts.
Elonav, a brand-new application dedicated to specifical needs of neurosurgeons.
Presentation of 3 innovative products based on Myrian® technology.
Strong growth, reaching operating balance.
suspension of the automatic drawdowns of bounds convertible into shares (« OCA »), initially planned in the contract signed on August 27, 2018.
Select your choice...Receive newsGet in touch with the investor serviceOther
By ticking this box, I agree to my data being used by Intrasense to respond to my request and to receive appropriate communications or information. I may withdraw my consent at any time by writing to the Data Protection Officer at dpo@intrasense.fr. For further information, please consult our Privacy Policy.
Please leave this field empty.
En cochant cette case, j'accepte que mes données soient utilisées par Intrasense pour répondre à ma demande et recevoir des communications ou des informations appropriées. Je peux retirer mon consentement à tout moment en écrivant au Délégué à la protection des données à dpo@intrasense.fr. Pour en savoir plus, consultez notre Politique de Confidentialité.
